Given the favorable nature of the mechanisms of action of SGLT2 inhibitors which are indeed multifactorial, it is highly conceivable that SGLT2 inhibitors can potentially attenuate atherogenesis and reduce subsequent CV event risks such as myocardial infarction and stroke, despite the vascular event risk profile identified in the EMPA-REG OUTCOME trial [10]. The gene discussed is SLC5A2; the disease is stroke disorder.